GlassScriptPhysician profile
Esmeralda Scott
NPI 1528652948
$3,469.40
in general payments reported to CMS, 2019-2025
29 companies · $653 in 2025
The $653 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $940 · 2023: $1,058 · 2024: $541 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $664.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $385.32 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $352.87 | 2022-2023 | |
| Amgen INC. | $271.06 | 2023 | Repatha, Otezla |
| Dynavax Technologies Corporation | $170.83 | 2024-2025 | Heplisav-B |
| Dexcom, INC. | $148.47 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Neurocrine Biosciences, INC. | $139.77 | 2024 | Ingrezza |
| Mayne Pharma Commercial LLC | $125.00 | 2023 | |
| Incyte Corporation | $125.00 | 2023 | Opzelura |
| Redhill Biopharma INC. | $124.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $121.82 | 2025 | Breztri |
| Ironwood Pharmaceuticals, INC | $117.73 | 2022-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $112.76 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $97.61 | 2022 | |
| Scynexis, INC. | $76.66 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $55.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $46.41 | 2025 | |
| Novartis Pharmaceuticals Corporation | $42.48 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.78 | 2023-2024 | |
| Esperion Therapeutics, INC. | $39.11 | 2023 | Nexletol |
| Gilead Sciences, INC. | $38.58 | 2023 | Epclusa |
| Pfizer INC. | $30.93 | 2024 | |
| Si-Bone, INC. | $27.38 | 2024 | |
| Tris Pharma INC | $24.99 | 2025 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.71 | 2024 | Xifaxan |
| Abbott Laboratories | $18.01 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.48 | 2025 | Jardiance |
| Antares Pharma, INC. | $14.95 | 2025 | Xyosted |
| Idorsia Pharmaceuticals US INC | $14.17 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esmeralda Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.